Search results

Light sensing small molecule given green light

Biotechnology company Kiora Pharmaceuticals has been given the go-ahead to start in-human testing of a novel “small molecule” treatment, known as KIO-301, for advanced vision loss in retinitis pigmentosa (RP). The phase 1b clinical trial will take place in Adelaide, Australia, and will begin enrolling participants towards the end of 2022.

A woman smiling at the camera with long dark hair

Diagnosis and beyond

Making yourself aware of the what you are entitled to, and understanding the diagnosis pathway for inherited sight loss, will put you in a stronger position to seek better support.